A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Exclusion Criteria

• •Laboratory and medical history parameters not within the Protocol-defined range
• •Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.
• •Has not recovered to ≤ Grade 1 from toxic effects of prior therapy.
• •Active autoimmune disease.
• •Known active central nervous system metastases and/or carcinomatous meningitis.
• •Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.
• •Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
• •Known history of human immunodeficiency virus (HIV); HIV 1/2 antibodies.